08:10 AM EDT, 05/29/2024 (MT Newswires) -- Milestone Pharmaceuticals ( MIST ) said Wednesday that the US Food and Drug Administration has accepted its New Drug Application for Cardamyst nasal spray for the management of paroxysmal supraventricular tachycardia, or PSVT, a type of arrhythmia or abnormal heart rhythm.

The company said the regulator's Prescription Drug User Fee Act target date is 10 months from the acceptance date of May 26.

Milestone said it is continuing commercial preparations for the anticipated launch of Cardamyst.

Price: 1.7300, Change: +0.08, Percent Change: +4.85